An inverse correlation between the morbidity of rheumatoid arthritis and daily intake of β-cryptoxanthin has been epidemiologically shown. In this study, we investigated the effects of β-cryptoxanthin on the metabolism of cartilage extracellular matrix in vivo and in vitro.
Introduction
Degenerative joint diseases such as rheumatoid arthritis (RA) and osteoarthritis (OA) are characterized by cartilage destruction with a loss of its ability to resist compressive and tensile forces due to degradation of the extracellular matrix (ECM) [1] [2] [3] . Cartilage is a specialized connective tissue whose ECM is highly organized having major macromolecules including type II collagen, hyaluronan, and aggrecan [4] . Aggrecans are present in cartilage as large aggregates interacting with hyaluronan and link proteins, and they are highly hydrated due to the negatively charged polysaccharide chains attached to the core proteins. This provides the cartilage with its ability to resist compressive loads. On the other hand, type II collagen forms a fibrillar meshwork that provides the tissue with tensile strength. These macromolecules function to maintain the homeostasis as well as the structural integrity of cartilage. In RA and OA, degradation of cartilage ECM exceeds its synthesis due to elevated activity of proteolytic enzymes, of which aggrecanases and matrix metalloproteinases (MMPs) are considered to be the major effectors [1] .
Increased aggrecanase-dependent aggrecan degradation has been reported to be detectable in RA and OA cartilage [2, 3] . The expression of aggrecanse-1, a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-4, in OA cartilage has been reported to correlate with the Mankin score of the disease [5] . On the other hand, aggrecanase-2 (ADAMTS-5) is constitutively expressed in human cartilage, but the expression of ADAMTS-5 is transiently elevated in human cartilage treated with interleukin (IL)-1, which is an inflammatory cytokine for the aggravation of RA and OA [6] . Furthermore, the deletion of active ADAMTS-5 in mice has been reported to protect their joints from the destruction occurring in the antigen-induced RA model [7] , or in the meniscus destabilization M A N U S C R I P T
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4 model of OA [8] , suggesting that aggrecan degradation by ADAMTS-5 is crucial for the development of arthritis at least in those animal models. These observations allow us to speculate that aggrecanase may become a target molecule for the treatment of RA and OA. At the moment, however, clinically effective inhibitors of aggrecanases for RA and OA have not been developed [2, 3] .
Currently, treatments to targeting cytokines, including anti-tumor necrosis factor α (TNFα) antibodies (Infliximab and Adalimumab), soluble TNF receptor (Etanercept), anti-IL-6 receptor antibody (Tocilizumab) and IL-1 receptor antagonist (Anakinra), are widely used for RA [9] , but these treatments have problems, especially in cost and the increased susceptibility to infection [10] . Therefore, therapeutics that can be safely used for a long term would be preferable. A few epidemiologic studies [11, 12] have shown the inverse correlation between morbidity of RA and daily intake of β-cryptoxanthin, suggesting that β-cryptoxanthin may prevent the development of RA. β-Cryptoxanthin is a widely distributed carotenoid pigment in citrus fruits, and most abundant in Citrus unshiu Marcovich (mandarin-orange) [13] . Like other carotenoids, β-cryptoxanthin exhibits an anti-oxidative action. In addition, a portion of intestinally absorbed β-cryptoxanthin has been reported to be enzymatically converted to retinoids in intestine and liver by β-carotene-15,15'-oxygenase [14] . Furthermore, several biological effects, e.g., an inhibition of carcinogenesis [15] , bone anabolic activity [16] , and an interference with bone resorption [17] , have been experimentally shown. However, the effects of β-cryptoxanthin on cartilage ECM metabolism have not been reported. In this study, we found the inhibitory effects of β-cryptoxanthin on cartilage degradation in antigen-induced arthritic rats. Using cultured human articular chondrocytes and synovial fibroblasts, we have demonstrated that β-cryptoxanthin prevents M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 5 aggrecan degradation by oppositely modulating the gene expression of aggrecanases and that of aggrecan core protein.
Materials and methods

Antigen-induced arthritis model
Female Lewis rats (6 weeks age, body weight 180 to 200 g, Charles River Laboratory Japan, Kanagawa, Japan) were immunized 21 and 14 days before induction of antigen-induced arthritis (AIA) with 1 mL of a suspension containing 0.5 mL each of methylated bovine serum albumin (mBSA) dissolved in phosphate buffered saline (PBS) and Freund's complete adjuvant by multiple subcutaneous injections into both flanks of the animals according to the method of Andersson et al. [18] . AIA was induced by intra-articular injection of 0.1 mg mBSA in 0.05 mL of PBS into the knee joint cavity. β-Cryptoxanthin (0.1, 0.3, and 1 mg/kg) (purity ≥95%; Shikoku Yashima Pure Chemicals, Tokushima, Japan) was orally administered to rats once a day starting 1 day before till the 3rd day after AIA induction (Total of 4 days).
On the day 4 after AIA induction, knee joints were dissected and fixed immediately for 2 days in 4% paraformaldehyde, and then decalcified in 22.5% formic acid/10% citric acid for 5 days followed by neutralization with 5% sodium sulfate for 1 day. Tissues were then embedded in paraffin, and the tissue sections (5 µm) mounted on slides were subjected to toluidine blue Relative expression level was calculated by ∆∆C T methods with the C T value of GAPDH.
Cell culture
Measurement of aggrecanase activity in porcine cartilage explants
Aggrecanase activity was determined using porcine cartilage explant culture as previously described [19] . Total glycosaminoglycan (GAG) released from the cartilage explants into the conditioned media was measured using a modification of the dimethylmethylene blue assay [20] .
Detection of aggrecan fragments
Aggrecan fragments caused by aggrecanase were analyzed by Western blotting using a mouse monoclonal antibody [BC-3] against the N-terminal neoepitope ARGSV of aggrecan generated by aggrecanase (a gift from Dr. C. Hughes from University of Cardiff), as described previously [21] . Immunoreactive aggrecan neoepitope (ARGSV) was visualized with enhanced chemiluminescence-Western-blotting detection reagents (GE Healthcare Bio-Sciences, Tokyo, Japan) using an Image Analyzer LAS-1000 Plus (GE Healthcare Bio-Sciences) according to the manufacturer's instructions.
Statistical analysis
A one-way ANOVA was performed using StatView version 5.0 (SAS Institute, SAS Campus Drive Cary, NC) for the data analysis. Independent student's t-test was applied for pair comparisons, and Fisher's PLSD post-hoc test was performed for multiple comparisons. P-value less than 0.05 was considered significant difference.
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Results
Anti-arthritic action of β-cryptoxanthin in antigen-induced arthritic rats
To investigate the anti-arthritic action of β-cryptoxanthin, AIA rats were used as an arthritic disease model [18] , and the knee joints were histologically evaluated. Poorly stained signals by toluidine blue were detected in AIA rats compared with untreated control rats, indicating the loss of glycosaminoglycans (GAG) ( Fig. 1A vs. B) . Orally administered β-cryptoxanthin interfered with the loss of GAG in a dose-dependent manner (Figs. 1C-E vs. B).
Immunohistochemical staining with the antibody recognizing the C-terminal neoepitope NITEGE sequence of aggrecan showed an increased aggrecanase-dependent fragmentation of aggrecan in AIA rat, which were largely localized with chondrocytes ( Fig. 1F vs. G) . The treatment of the AIA rats with β-cryptoxanthin suppressed the generation of NITEGE fragments (Figs. 1H-J vs. G). Imaging analysis of immunostained NITEGE fragments revealed that β-cryptoxanthin dose-dependently decreased aggrecan degradation in AIA rats ( Fig. 1K) . These observations suggested that β-cryptoxanthin exerts an anti-arthritic action through interference with the aggrecanase-mediated aggrecan degradation.
β-Cryptoxanthin blocks IL-1α-induced aggrecan degradation in porcine cartilage
Next, we examined whether β-cryptoxanthin affects aggrecan degradation in cartilage stimulated with IL-1α. As shown in Fig. 2A aggrecan generated by the IL-1α-induced aggrecanase activity (Fig. 2B ). There were no detectable aggrecan fragments produced by MMPs under these experimental conditions (Fig.   S1 ). These observations suggest that β-cryptoxanthin blocks the aggrecan degradation in cartilage by decreasing aggrecanase activity.
Effects of β-cryptoxanthin on the gene expression of ADAMTSs-4 and -5, and aggrecan core protein in human articular chondrocytes
To clarify the effect of β-cryptoxanthin on the gene expression of ADAMTSs-4 and -5 in articular chondrocytes, human articular chondrocytes encapsulated in alginate beads were treated with IL-1α in the presence or absence of β-cryptoxanthin. As shown in Fig. 3A, β-cryptoxanthin suppressed the IL-1α-induced gene expression of ADAMTSs-4 and -5 in a dose-dependent manner (upper and lower panels, respectively). Tissue inhibitor of metalloproteinases 3 (TIMP-3) inhibits the enzymatic activity of ADAMTSs-4 and -5 [22] , but there were no significant changes in the mRNA level of TIMP-3 in the β-cryptoxanthin-treated chondrocytes (Fig. 3B ). On the other hand, IL-1α slightly decreased the mRNA levels of aggrecan core protein in chondrocytes, but β-cryptoxanthin augmented the gene expression of aggrecan core protein above the level of the control chondrocytes (Fig.   3C ). Taken together, these results suggest that β-cryptoxanthin protects cartilage from degradation by suppressing the gene expression of ADAMTSs-4 and -5 and augmenting that of aggrecan core protein in human articular chondrocytes.
Discussion
Aggrecanases play central roles in both physiological and pathological catabolism of cartilage M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
11 matrix [2, 3] , and ADAMTS-4 is considered to participate in the degradation of ECM molecules in joint tissues, including those in cartilage and ligaments. Therefore, the suppression of ADAMTS expression is considered to be an effective way to block the cartilage destruction in RA and OA [2, 3] .
The expression of ADAMTSs-4 and ADAMTS-5 mRNAs is induced by IL-1, TNFα, the combination of IL-1 and oncostatin M, or transforming growth factor-β [6, 23] , whereas n-3 fatty acids [24] and fibroblasts growth factor 2 [6] suppress of the expression of ADAMTS-4 and ADAMTS-5, respectively. A few natural organic compounds have been reported to block the inflammatory cytokine-induced production of ADAMTSs in chondrocytes or synovial fibroblasts. For example, triptolide from the Chinese herb, Tripterygium wilfordii Hook F suppresses the expression of ADAMTS-4 in chondrocytes [25] , and nobiletin, a citrus polymethoxy flavonoid, blocks the expression of ADAMTSs-4 and -5 in collagen-induced arthritic mice model [26] . β-Cryptoxanthin described here is a novel natural compound that prevents cartilage destruction both in-vitro and in-vivo models of arthritis. The efficacy of the orally administered β-cryptoxanthin in blocking cartilage destruction in the rat AIA model suggests its potential as an anti-arthritic agent in OA and RA.
Regarding the control of enzymatic activity of aggrecanases, TIMP-3 has been reported to be an important cartilage protectant due to the inhibition of ADAMTSs-4 and -5 activity [22] . In this study, we have demonstrated that β-cryptoxanthin suppressed the IL-1α-induced gene expression of ADAMTSs-4 and -5 in human chondrocytes, but it did not alter the gene expression of TIMP-3 in human chondrocytes. On the contrary, we found that β-cryptoxanthin augments the gene expression of aggrecan core protein in human chondrocytes. Aggrecan is the most abundant proteoglycan in cartilage, and M A N U S C R I P T
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12 aggrecanase-mediated degradation of aggrecan is observed at the initial phase of cartilage destruction [1] [2] [3] , which makes collagen fibrils more susceptible to collagenases [27] .
Therefore, the augmentation of aggrecan biosynthesis shifts cartilage metabolism towards the anabolic state. Together, these results indicate that β-cryptoxanthin prevents cartilage from catabolism and helps to maintain homeostasis of the cartilage tissue.
It has been reported that the serum concentration of β-cryptoxanthin is approximately 0.1 to 0.2 µM, whereas more than 1 µM is detectable in Japanese inhabitants who usually take Citrus unshiu Marcovich [28, 29] . Thus, our findings support the epidemiological studies reporting an inverse correlation between the morbidity of RA and the daily intake of β-cryptoxanthin. In contrast, the daily intake of other carotenoid pigments does not correlate with the incidence of RA [11, 12] . We have presented preliminary data demonstrating that β-carotene and astaxanthin suppressed the gene expression of ADAMTS-4, but not that of ADAMTS-5, while β-cryptoxanthin decreased the mRNA level of both ADAMTSs-4 and -5 in cultured human synovial fibroblasts (Fig. S2 ). Furthermore, since ADAMTS-5 has been shown to be the major aggrecanase, at least in mouse arthritis models [7, 8] , the blocking effect of β-cryptoxanthin on ADAMTS-5 expression may be a key factor related to the morbidity of RA.
Orally administered β-cryptoxanthin has been reported to be partially converted to retinoids by β-carotene-15,15'-oxygenase [14] , which thereby exhibits provitamin A activity.
Although retinoic acid has been reported to up-regulate the expression of ADAMTS-5 mRNA [30] , we have found that all-trans retinoic acid (1 µM) did not influence the gene expression of ADAMTS-5 but suppressed that of ADAMTS-4 in human synovial fibroblasts (Fig. S3 ).
Furthermore, we conclude that β-cryptoxanthin is the molecule that suppresses ADAMTS-5 M A N U S C R I P T
13 expression, but further experiments are necessary to clarify the transcriptional regulatory mechanism of β-cryptoxanthin.
In conclusion, we have provided novel evidence that β-cryptoxanthin exerts chondroprotective actions by inhibition of aggrecan degradation by suppressing ADAMTSs-4 and -5 expression and augmenting aggrecan synthesis in vivo and in vitro. Our study sheds light on the molecular mechanism behind the epidemiologic observation that daily intake of β-cryptoxanthin reduces the morbidity of RA.
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